trending Market Intelligence /marketintelligence/en/news-insights/trending/XLMf0B2X-IgOouvJA2e7LA2 content esgSubNav
In This List

Emergent wins approval to sell typhoid vaccine in 5 more EU countries

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Emergent wins approval to sell typhoid vaccine in 5 more EU countries

Emergent BioSolutions Inc. secured approval to sell its typhoid fever vaccine in five additional European Union member states — France, Portugal, Poland, Czech Republic and Slovakia.

The company's Vivotif oral vaccine is used to prevent typhoid fever, a potentially severe and life-threatening infection caused by the bacterium Salmonella enterica serovar Typhi, in adults and children aged 5 and older.

The Gaithersburg, Md.-based biotech company is selling the drug under the name Vivotif in the U.S. and Europe and as Typhoral L in Germany.